FDA Leadership’s “Blind Spots” Lead to a Surge in Medical Device and Drug Recalls

FDA Leadership’s “Blind Spots” Lead to a Surge in Medical Device and Drug Recalls The FDA possesses the legal authority, institutional framework, and technical expertise necessary to solve this problem. What is missing is leadership’s willingness to demand the standards that once defined American drug regulation and legacy records of a low number of recalls.